| Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study S Luminari, M Merli, S Rattotti, V Tarantino, L Marcheselli, F Cavallo, ... Blood, The Journal of the American Society of Hematology 134 (10), 798-801, 2019 | 73 | 2019 |
| Thrombocytopenia and hemorrhagic risk in cancer patients G Avvisati, MC Tirindelli, O Annibali Critical reviews in oncology/hematology 48, S13-S16, 2003 | 72 | 2003 |
| Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial L Cicconi, U Platzbecker, G Avvisati, F Paoloni, C Thiede, M Vignetti, ... Leukemia 34 (3), 914-918, 2020 | 68 | 2020 |
| Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd … F Gay, C Cerrato, DR Scalabrini, M Galli, A Belotti, E Zamagni, A Ledda, ... Blood 132, 121, 2018 | 68 | 2018 |
| Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis G Palladini, B Paiva, A Wechalekar, M Massa, P Milani, M Lasa, ... Blood cancer journal 11 (2), 34, 2021 | 61 | 2021 |
| PD-1/PD-L1 checkpoint in hematological malignancies O Annibali, A Crescenzi, V Tomarchio, A Pagano, A Bianchi, A Grifoni, ... Leukemia Research 67, 45-55, 2018 | 49 | 2018 |
| Rituximab as single agent in primary MALT lymphoma of the ocular adnexa O Annibali, F Chiodi, C Sarlo, M Cortes, FM Quaranta-Leoni, ... BioMed Research International 2015 (1), 895105, 2015 | 43 | 2015 |
| High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma L Bertamini, S Oliva, D Rota-Scalabrini, L Paris, S Morè, P Corradini, ... Journal of Clinical Oncology 40 (27), 3120-3131, 2022 | 42 | 2022 |
| Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature O Annibali, M Napolitano, G Avvisati, S Siragusa Critical Reviews in Oncology/Hematology 124, 41-50, 2018 | 40 | 2018 |
| Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review F Marchesi, O Annibali, E Cerchiara, MC Tirindelli, G Avvisati Critical Reviews in Oncology/Hematology 80 (3), 331-346, 2011 | 40 | 2011 |
| Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML MP Martelli, R Rossi, A Venanzi, M Meggendorfer, VM Perriello, G Martino, ... Blood, The Journal of the American Society of Hematology 138 (25), 2696-2701, 2021 | 36 | 2021 |
| Fibrin glue therapy for severe hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation MC Tirindelli, GP Flammia, P Bove, R Cerretti, L Cudillo, G De Angelis, ... Biology of Blood and Marrow Transplantation 20 (10), 1612-1617, 2014 | 36 | 2014 |
| Fibrin glue for refractory hemorrhagic cystitis after unrelated marrow, cord blood, and haploidentical hematopoietic stem cell transplantation MC Tirindelli, G Flammia, F Sergi, R Cerretti, L Cudillo, A Picardi, ... Transfusion 49 (1), 170-175, 2009 | 36 | 2009 |
| Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis S Bringhen, M Offidani, S Palmieri, F Pisani, R Rizzi, S Spada, ... Critical reviews in oncology/hematology 130, 27-35, 2018 | 34 | 2018 |
| IgM multiple myeloma: report of four cases and review of the literature O Annibali, MT Petrucci, PD Bianco, C Gallucci, A Levi, R Foà, G Avvisati Leukemia & lymphoma 47 (8), 1565-1569, 2006 | 33 | 2006 |
| Early diastolic dysfunction after cancer chemotherapy: primary endpoint results of a multicenter cardio-oncology study V Calabrese, P Menna, O Annibali, G Armento, A Carpino, E Cerchiara, ... Chemotherapy 63 (2), 55-63, 2018 | 30 | 2018 |
| Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis O Annibali, MT Petrucci, V Martini, MC Tirindelli, A Levi, C Fossati, ... Cancer 103 (3), 582-587, 2005 | 27 | 2005 |
| CD123 Is Consistently Expressed on NPM1-Mutated AML Cells VM Perriello, I Gionfriddo, R Rossi, F Milano, F Mezzasoma, A Marra, ... Cancers 13 (3), 496, 2021 | 22 | 2021 |
| Protective isolation for patients with haematological malignancies: a pilot study investigating patients’ distress and use of time O Annibali, C Pensieri, V Tomarchio, V Biagioli, M Pennacchini, A Tendas, ... International journal of hematology-oncology and stem cell research 11 (4), 313, 2017 | 22 | 2017 |
| Minimal residual disease evaluation by multiparameter flow cytometry and next generation sequencing in the forte trial for newly diagnosed multiple myeloma patients S Oliva, E Genuardi, A Belotti, PMM Frascione, M Galli, A Capra, ... Blood 134, 4322, 2019 | 21 | 2019 |
